Health Canada Approves Arcutis' Przoryve Cream for Young Children with Atopic Dermatitis
ARQT sits 65% above its 52-week low of $15.1.
Summary
Health Canada approved Przoryve cream 0.05% for children aged 2 to 5 years with mild to moderate atopic dermatitis. This expands the product's label into a new geography and a younger pediatric population. The approval follows the FDA's acceptance of a supplemental New Drug Application for ZORYVE cream 0.05% in July, indicating a broader regulatory push for the franchise. Arcutis reported strong Q2 results with product revenue up 59% year-over-year, driven by ZORYVE sales. This Canadian approval adds another revenue stream and validates the product's safety and efficacy in a vulnerable age group.
At the time of this announcement, ARQT was trading at $24.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $15.10 to $31.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.